Alimentary Health and Norgine to evaluate probiotic technology
For development as a drug to treat gastrointestinal conditions
Cork, Ireland-based biotechnology firm Alimentary Health Limited (AH) has joined forces with Norgine, a European pharmaceutical company with a portfolio of development projects in the areas of gastroenterology, hepatology and supportive care.
Under the deal, AH and Norgine will both evaluate AH’s proprietary probiotic technology for development as a medicinal product for the treatment or management of gastrointestinal (GI) conditions.
Norgine will have the option to negotiate a licence to commercialise the technology. AH will receive an upfront fee and will be eligible for additional milestone payments.
No financial details were revealed.
Barry Kiely, chief executive of Alimentary Health, said: ‘We believe that the full therapeutic potential of probiotic technology is yet to be tapped. This partnership is further validation of AH’s technology and recognition of our position at the forefront of research into probiotic technology.’
Norgine’s vp of corporate and business development Paul Pay said the research collaboration was significant ‘as it signals our first move into the growing field of probiotics’.